Complications of subspecialty ophthalmic care: Endophthalmitis after intravitreal injections of anti-vascular endothelial growth factor medications

Luis J. Haddock, David J. Ramsey, Lucy H. Young

Research output: Contribution to journalReview article

12 Scopus citations

Abstract

The use of medications directed against vascular endothelial growth factor (VEGF) signaling has revolutionized the treatment of age-related macular degeneration (AMD) and many other retinal diseases in the last decade. However, the rapidly increasing use of these agents has led to a rise in treatment-Associated complications. One of the most feared by patients and ophthalmologists is post-injection endophthalmitis, which can result in severe vision loss and, in rare cases, loss of the eye. The aim of this article is to review the incidence, clinical findings, risk factors, management, and visual outcomes in cases of endophthalmitis following intravitreal injections of anti-VEGF medications.

Original languageEnglish (US)
Pages (from-to)257-262
Number of pages6
JournalSeminars in Ophthalmology
Volume29
Issue number5-6
DOIs
StatePublished - Sep 1 2014
Externally publishedYes

Keywords

  • Age-related macular degeneration (AMD)
  • Endophthalmitis
  • Intravitreal injection
  • Post-injection complications
  • Vascular endothelial growth factor (VEGF)

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Complications of subspecialty ophthalmic care: Endophthalmitis after intravitreal injections of anti-vascular endothelial growth factor medications'. Together they form a unique fingerprint.

  • Cite this